 Zai Lab Limited NASDAQ: ZLAB announced topline results from Phase 1b study of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis CPP. ZL-1102 is an investigational, novel human VH antibody fragment targeting the IL-17A cytokine. 